Compare SEAT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | SCLX |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | 768 | 30 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6M | 52.9M |
| IPO Year | N/A | N/A |
| Metric | SEAT | SCLX |
|---|---|---|
| Price | $6.76 | $11.08 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $18.06 | N/A |
| AVG Volume (30 Days) | ★ 92.9K | 58.3K |
| Earning Date | 05-05-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $122.52 |
| Revenue Next Year | $4.60 | $186.30 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $3.95 |
| 52 Week High | $35.00 | $34.27 |
| Indicator | SEAT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 76.22 |
| Support Level | $6.08 | $7.73 |
| Resistance Level | $7.85 | $12.30 |
| Average True Range (ATR) | 0.67 | 0.91 |
| MACD | -0.08 | 0.48 |
| Stochastic Oscillator | 31.30 | 78.49 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.